Moscow: Russia (Russia) has approved the second Covid-19 Vaccine of Covid-19 after initial trials. President Vladimir Putin announced this news at a government meeting on Wednesday. The vaccine was developed by the Vector Institute in Siberia, and it completed early-stage human trials last month. However, its results have not been published yet and a large-scale trial known as Phase III has not yet begun.
In comments broadcast on state TV, Putin said, “We need to increase production of the first and second vaccines. We are continuing to cooperate with our foreign partners and will promote our vaccines abroad.” This vaccine, named peptide-based EpiVacCorona, is the second in terms of being licensed for use in Russia. The vaccine has been subjected to a placebo-controlled trial on 100 volunteers between the ages of 18 and 60 in the city of Novosibirsk.
The vaccine Sputnik V, developed by Moscow’s Gamalaya Institute, was licensed for domestic use in August. This vaccine, based on the adenovirus vector, was also registered before Phase III trials. It is currently undergoing testing in 40,000 participants in Moscow.
Human trials may begin in November or December
A large-scale human trial of Epivaccorona is likely to begin in November or December, the TASS news agency quoted Consumer Protection Watchdog Rospotrebnadzor, which oversees the institute.
According to the Interfax news agency, 30,000 volunteers are expected to be involved in the trial, of which the first 5,000 will be residents of Siberia.
Russia is at number four among the most affected countries in the world
According to the Ministry of Health, hundreds of people who are at high risk of coronovirus infection due to their profession have been given ‘Sputnik V’, but the vaccine has not yet come into normal use.
Since the onset of the epidemic, Russia is ranked fourth in the list of the worst affected countries, after Russia, the United States, India and Brazil. Where more than 1,340,000 infection cases have been registered so far.
Another vaccine against COVID-19 is being developed by the Chumakov Institute in St. Petersburg. Currently, it is being planned to start its initial phase of clinical trials in which around 300 people are going to attend on 19 October.
